PV pharm branch, vendor, cage 0U9U0

AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,726.24 on August 25, 2025, by the Defense Logistics Agency Medical Supply Chain, a defense-focused federal agency. This firm fixed-price delivery order, which represents no set-aside, is scheduled for completion by August 26, 2025, with performance based in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) designated SPE2DX with the DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime indefinite delivery vehicle provides comprehensive global pharmaceutical support, enabling the company to supply a broad range of pharmaceutical products and medical supplies including specialty medications, brand-name and generic drugs, vaccines, and medical devices to support military healthcare programs worldwide.

As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates extensive delivery of pharmaceutical products across multiple therapeutic domains, including diabetes medications, neurological treatments, pain management pharmaceuticals, antibiotics, and specialized medical supplies. All of the company's reviewed contract awards have been competitively awarded without set-aside designations, reflecting AmerisourceBergen's capability to meet federal procurement requirements through open competition. The Defense Logistics Agency is planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards involving several contractors, positioning AmerisourceBergen as a key strategic partner in this initiative.